EUVIMEDEUVIMED entdecken
Crossref

Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)

Nina N Sanford iD, Qian Shi iD, David M Hein iD, William A Hall

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djae313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Nina N Sanford und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Benchmarking, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Dedman Family Scholar in Clinical Care, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The National Clinical Trials Network (NCTN) is the largest government-sponsored organization in the United States; it is tasked with funding randomized controlled trials in oncology. It is unknown whether there are differences in study design by treatment modality. We evaluated differences in methodology between trials testing radiation therapy (RT) vs systemic therapy.

Methods

The Clinical Trials Support Unit website was used to identify active randomized controlled trials of systemic therapy or RT across NCTN cooperative groups through December 31, 2023. Studies in disease sites with more than 5 RT trials were included. Each trial’s protocol was reviewed to obtain key design information that was descriptively compared: primary endpoint, hypothesis testing type (superiority vs noninferiority), noninferiority margin, hypothesized effect size, power, and statistical significance level.

Results

A total of 186 randomized controlled trials (142 systemic therapy, 44 RT) were examined. Comparing primary endpoints, 59.1% vs 26.8% of RT vs systemic therapy trials, respectively, had a primary endpoint of overall survival. Nearly one-third (31.2%) of RT trials were noninferiority vs 6.3% of systemic therapy trials. Among breast cancer trials, 75% of RT studies were noninferiority vs 11.1% systemic therapy. Target effect size, power, and statistical significance level were similar by treatment modality within tumor types and disease settings.

Conclusion

Among NCTN cooperative group randomized controlled trials, there were marked differences in study design between RT vs systemic therapy trials. A higher benchmark for defining success for RT interventions was observed, with greater emphasis on overall survival as the primary endpoint. This finding may reflect differences in therapeutic mechanism by modality and types of study questions posed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicBenchmarkingNeoplasmsHumansNational Cancer Institute (U.S.)United StatesResearch DesignTreatment Outcome

Autor:innen und Institutionen

  • Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, United States.
  • Lyda Hill Department of Bioinformatics, The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
  • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States.

ORCID-Profile: Nina N Sanford, Qian Shi, David M Hein

Förderung

  • Dedman Family Scholar in Clinical Care
  • AstraZeneca

Zitieren

APA

Sanford, N. N., Shi, Q., Hein, D. M., & Hall, W. A. (2025). Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI). JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae313

Vancouver

Sanford NN, Shi Q, Hein DM, Hall WA. Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI). JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae313

BibTeX
@article{Sanford2025,
  author = {Sanford, Nina N and Shi, Qian and Hein, David M and Hall, William A},
  title = {Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djae313}
}
Kostenlos starten →